Company Overview
Snapshot
Founded in October 2018, Kamari Pharma operates with 1–10 employees. The company has raised $31 million across 3 funding rounds from 4 investors, with Pontifax participating as a lead investor. In June 2025, Kamari Pharma secured $23 million in Series A financing to advance its lead program, KM023, into clinical development for rare genetic skin diseases.
Business overview
Kamari Pharma is a biopharmaceutical company focused on developing and commercializing proprietary small molecule inhibitors of TRPV3, a cation channel primarily expressed in keratinocytes. The company targets dermatological conditions with unmet medical needs, including Olmsted syndrome, severe keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, Kamari Pharma leverages its expertise in biologicals and molecules to address these conditions.
Strategic signal
In April 2026, Kamari Pharma announced a name change and initiated clinical trials for its dermatological drug. This development signals a significant advancement in the company's product pipeline and its transition into a more mature clinical-stage biopharmaceutical entity, indicating potential for future market entry and commercialization.
Log in to access full profile ›Company Intelligence Q&A
- What was Kamari Pharma's most recent funding round?
- In June 2025, Kamari Pharma announced the closing of a $23 million Series A financing round. This funding was co-led by BRM Group and Pontifax.
- What is the primary focus of Kamari Pharma's drug development?
- Kamari Pharma is focused on developing and commercializing proprietary small molecule inhibitors of TRPV3, a cation channel, for the treatment of various dermatological conditions with unmet needs.
- Which dermatological conditions does Kamari Pharma's research target?
- Kamari Pharma's research targets various skin disorders, including Olmsted syndrome, severe keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.
- When did Kamari Pharma initiate clinical trials for its dermatological drug?
- In April 2026, Kamari Pharma began clinical trials for its dermatological drug, coinciding with a company name change.
- What was Kamari Pharma's funding activity in September 2022?
- In September 2022, Kamari Pharma secured an investment from Guangzhou Sino-Israel Biotech Investment Fund (GIBF).